SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Aulos Bioscience Reports Imneskibart-Avelumab NSCLC Trial Results

In checkpoint inhibitor-refractory adenocarcinoma non-small cell lung cancer, the regimen had median progression-free survival of 5.8 months and a confirmed objective response rate of 21%. The body text is truncated after “86% dis”.

Related stories